diet doc tirzepatide for Weight Loss: Breakthrough Treatment or Risky Gamble? Lose up to 6 kg

Este producto requiere conservacin de cadena de fro, por tanto se recomienda seguir las instrucciones del empaque

Clinical treatment

Source: Bloomberg The lawsuit in US federal court in New Jersey centers on an ad that Lilly started airing in April, which relies on the head-to-head Surmount-5 study to say that people on Zepbound lost an average of 50 pounds, while those on Wegovy lost an average of 33 pounds, Novo argues that a better comparison would be two different studies, one in which Novos high-dose Wegovy showed average weight loss of 47 pounds and one in which Zepbound helped people lose an average of 48 pounds

Food and Drug Administration (FDA) has warned against the use of GLP-1 RA by individuals with personal or family history of medullary thyroid cancer and hereditary conditions associated with this type of cancer. With this in mind, investigators evaluated whether people with type 2 diabetes who take GLP-1 RAs are at a higher risk of developing thyroid cancer compared with those taking other common diabetes medications

However, it is important to note that the number of cases reported is small and the relationship between semaglutide use and MEN is not yet fully understood